Test reveals gender early in pregnancy: Ethicists fear use in sex selection
By Boston Globe,
Boston Globe
| 06. 27. 2005
First came the home pregnancy test. Now here comes the home gender test.
A new blood test being marketed to American women offers them the chance to find out whether they are having a boy or a girl almost as soon as they realize they are pregnant, as early as five weeks along.
Just two or three days after mailing the test overnight to a Lowell lab for processing, a pregnant woman can know what color to paint the nursery -- or even decide whether to get an abortion if she wants a child of the opposite sex, a prospect that worries ethicists.
The $275 test works by detecting and analyzing fetal DNA floating in the mother's blood, a method that researchers say holds promise for serious clinical uses, from cancer testing to prenatal diagnosis of Down syndrome.
The test, called the Baby Gender Mentor, is meant for ''the type of woman who can't wait to open Christmas presents," said Sherry Bonelli, president of Mommy's Thinkin', the company that is marketing the test at an online pregnancy store.
But ethicists...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...